Investment firm Carlyle and Inova today announced a long-term funding partnership to accelerate growth, product innovation and M&A activities.
Lyon, France-based Inova develops software platforms dedicated to life sciences to enable pharmaceutical and biotech companies to collaborate on workstreams across organizations.
Inova touts its flagship product, “Inova Enterprise,” as a collaborative tool used to manage all processes related to outsourced innovation for laboratories and biotechs, enabling lead sourcing, transaction execution, alliance management and virtual events.
Carlyle’s investment aims to support Inova as it enters its next phase of growth, with the investment thesis centered around accelerating Inova’s internal expansion, including the strengthening of its presence in China. Other goals include investing in Inova’s product suite and differentiated platform, as well as helping with strategic acquisitions.
“We are fully committed to the digital transformation of life science partnering and, with Carlyle’s support, we will greatly accelerate our ambitious development plan to scale Inova and leverage our market-leading platform along the entire partnering value chain, from initial lead sourcing to alliance management,” Inova CEO Gilles Toulemonde said in the release. “With Carlyle’s support, we look forward to accelerating our innovation roadmap and strategically acquire technologies that complement our global vision for biopharmaceutical partnering.”
Carlyle Europe Technology Partners IV will provide the equity for the financing.
“We have been extremely impressed by Inova’s team and product leadership,” Carlyle Europe Technology Partners co-head Vladimir Lasocki said. “We are delighted to partner with the company and see a tremendous opportunity to help further build their mission-critical product suite, accelerate their global expansion, and become the leading platform serving the partnering industry which lies at the heart of life sciences. We believe that Inova has significant growth opportunities and look forward to leveraging our strategic industry knowledge and global network as the company enters its next phase of development. “
Filed Under: Drug Discovery, Drug Discovery and Development
